Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-vvkck Total loading time: 0 Render date: 2024-04-26T13:21:15.043Z Has data issue: false hasContentIssue false

89 - Mexiletine

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Mexitil

Generic?

• Yes

Class

• Antiarrhythmic

Commonly Prescribed for

(FDA approved in bold)

Ventricular arrhythmias

• Symptomatic myotonia (myotonia congenita, myotonic dystrophy)

• Intractable headache

• Trigeminal autonomic cephalalgia

How the Drug Works

• An oral analog of lidocaine. Class 1b antiarrhythmic agent that depresses phase 0; it reduces the rate of rise of the action potential (not the duration) by inhibiting the inward sodium current but not affecting resting membrane potential. It acts more on faster than slower heart rates. It has actions on surfaces and membranes of skeletal muscle and neuronal sodium-channel blocking properties. It also reduces the effective refractory period in Purkinje fibers in the heart

How Long Until It Works

• Antiarrhythmic effect will occur within hours, although it may take time to find optimal dose. May take more time (days or weeks) to see relief and determine most effective dose in myotonia or pain disorders

If It Works

• Continue to use with appropriate monitoring

If It Doesn't Work

• Check serum levels and if not effective change to an alternative agent

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Myotonia: quinine and other AEDs are occasionally used. Phenytoin is also effective but has similar antiarrhythmic properties and may interact with mexiletine

Tests

• Monitor hepatic enzymes and CBC during therapy. Obtain ECG at baseline and for any new symptoms. Check a serum mexiletine level to guide therapy and for any AEs

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• Drug effect blocking sodium channels

Notable AEs

• GI AEs (nausea, vomiting, heartburn) are most common. CNS AEs (tremor, nervousness, coordination difficulties, blurred vision, confusion) are much more common when serum levels exceed 2mcg/mL

Life-Threatening or Dangerous AEs

• New or worsening cardiac arrhythmias

• Acute hepatic injury (usually in the first few weeks of therapy)

• Blood dyscrasias, including leukopenia (rare)

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 328 - 330
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Mexiletine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.090
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Mexiletine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.090
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Mexiletine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.090
Available formats
×